CD47 and neoplasm: Similarly, pairing CD47 blockade with DNA damage response therapies, including poly (ADP-ribose) polymerase (PARP) inhibitors, has shown synergistic potential by promoting immunogenic stress responses and facilitating tumor cell recognition [47,48].